DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wwbhdn/glomerulonephritis) has announced the addition of the "Glomerulonephritis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adienne Pharma & Biotech
- Alexion Pharmaceuticals, Inc.
- Anthera Pharmaceuticals Inc.
- Avexxin AS
- Biogen, Inc.
- Cyclacel Pharmaceuticals, Inc.
- FibroStatin SL
- Fortress Biotech, Inc.
- GlaxoSmithKline Plc
- Hansa Medical AB
- Mallinckrodt Plc
- Pfizer Inc.
- Pharmalink AB
- Rigel Pharmaceuticals, Inc.
- Toray Industries, Inc.
Drug Profiles
- Adipose Stem Cell Therapy for IgA Nephropathy
- AVX-235
- belimumab
- blisibimod
- budesonide
- corticotropin
- DEXM-74
- Drug to Inhibit GPBP for Glomerulonephritis and Cancer
- eculizumab
- Endoglycosidase of Streptococcus pyogenes
- fostamatinib disodium
- Mubodina
- PBF-1472
- PF-1355
- Recombinant Enzyme for Immunoglobulin A Nephropathy
- rituximab
- seliciclib
- Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis
- Vaccine to Target CD40 for Membranous Glomerulonephritis
For more information visit http://www.researchandmarkets.com/research/wwbhdn/glomerulonephritis
